Photys Therapeutics
PrivateLast Round
Series A
Sep 8, 2022
Total Funding Raised
$75M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Photys Therapeutics operates in Healthcare & Life Sciences and is based in Waltham, Massachusetts. Its latest recorded funding round was a Series A round in September 2022.
Photys Therapeutics is a biotechnology company that develops proximity-based therapeutics, including its proprietary PHICS (Phosphorylation-Inducing Chimeric Small molecules) platform, to modulate protein function for the treatment of oncology, autoimmune, and cardiometabolic diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Photys Therapeutics Comparables
Compare Photys Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Ambagon Therapeutics | 82% | |
| Vicinitas Therapeutics | 78% | |
| General Proximity | 78% |
For institutional investors. Book with your work email.
Photys Therapeutics Funding Rounds
Historical fundraising activity
For institutional investors. Book with your work email.
Photys Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| MPM Capital | Series A |
| Omega Funds | Series A |
| Mass General Brigham Innovation | Series A |
| MPM BioImpact | Series A |
| Arkin Holdings | Series A |
| 8VC | Series A |
| Longwood Fund | Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 22, 2026
Monthly visitors increased 32% MoM.
- Feb 20, 2025
Licensed a phase 1-ready IRAK4 degrader from Polymedbiopharma.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingAug 14, 2026
Under a 2025 licensing agreement, Photys Therapeutics, Inc. develops PHT-776/HPB-143, an oral IRAK4 PROTAC degrader, with exclusive rights outside Greater China and Southeast Asia, while its Phase I trial initiates and doses initial healthy participants at Huashan Hospital in China on Aug 14th '26.
For institutional investors. Book with your work email.
Photys Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Photys Therapeutics's valuation, stock price, and market status.
Is Photys Therapeutics a public or private company?
Photys Therapeutics is a private company.
What is the current stock price of Photys Therapeutics?
Photys Therapeutics is a private company, so its shares have no public market price. Caplight tracks Photys Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Photys Therapeutics worth (valuation)?
Valuation information for Photys Therapeutics is not publicly available.
Can I buy Photys Therapeutics stock?
Photys Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Photys Therapeutics's last funding round?
Photys Therapeutics's most recent funding round was Series A on September 8, 2022.
Who are the main investors in Photys Therapeutics?
Key investors in Photys Therapeutics include MPM Capital, MPM BioImpact.
Will Photys Therapeutics IPO soon?
No public IPO plans have been announced for Photys Therapeutics.
How can I track Photys Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Photys Therapeutics's shares on secondary markets.